Cancer Capital Corp   (CNCL)
Other Ticker:  
    Sector  Financial    Industry Blank Checks
   Industry Blank Checks
   Sector  Financial
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cancer Capital Corp
Cancer Capital Corp is a financial services company that specializes in providing investment capital for cancer research and development. Their focus is on supporting and financing small and medium-sized biotech companies that are dedicated to finding new breakthroughs and treatments for cancer. The company aims to bridge the funding gap in cancer research and help bring promising therapies to market. Cancer Capital Corp also works closely with academic institutions, pharmaceutical companies, and other stakeholders in the oncology field to foster collaboration and accelerate the development of innovative cancer treatments.

   Company Address: 2157 S. Lincoln Street Salt Lake City 84106 UT
   Company Phone Number: 323-2395   Stock Exchange / Ticker: CNCL
   CNCL is expected to report next financial results on March 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cancer Capital Corp

Cancer Capital Corp , deterioration in the corporate performance during the first quarter of 2023

Investors have been closely monitoring Cancer Capital Corp's (CNCL) financial performance during the earnings cycle of fiscal January to March 31, 2023. While they did not anticipate any significant changes at the company's top-line, they noted the operating deficit of $-0.005699 million in the same quarter. This figure has seen a decrease since the first quarter of 2021, from $-0.00282 million, but investors are still very interested in when the company will start to generate revenue.
It's not uncommon for corporations to go through rough patches as they strive to identify successful sources of revenue. The first quarter of 2023 was one such rough period for Cancer Capital Corp. During this time, the company saw a net loss of $-0.011 million. However, this could be a temporary hurdle that the company will overcome through adjustments and strategic planning.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com